TWiV 879: Indolent, resistant, and losing our TMPRSS

March 24, 2022

TWiV reviews the emergence of remdesivir-resistant SARS-CoV-2 during treatment of a persistently infected immunocompromised patient, and how altered TMPRSS2 utilization by the Omicron variant influences infectivity and fusion.

Hosts: Vincent Racaniello, Alan Dove, Rich Condit, Kathy Spindler, and Brianne Barker

Click arrow to play
Download TWiV 879 (75 MB .mp3, 124 min)
Subscribe (free): Apple PodcastsGoogle PodcastsRSSemail

Become a patron of TWiV!

Weekly Picks 1:21:44

BrianneNSURP 2022
Kathy Virology Jobs
Rich10 Steps from Seed to Cup (Graphic)
AlanFathoms: The World in The Whale, by Rebecca Giggs

Listener Picks

JeremyArchaeology of Light

Intro music is by Ronald Jenkees

Send your virology questions and comments to

Leave a Reply

Your email address will not be published. Required fields are marked *

2 comments on “TWiV 879: Indolent, resistant, and losing our TMPRSS

  1. H. Bradford Hawley, MD Mar 25, 2022

    Since studies have now demonstrated that unlike Delta and other previous versions of the SARS-C0V-2 the Omicron variant prefers endosomal entry, it follows that chloroquine/hydroxychloroquine might be a clinically useful therapy! In vitro data revealed that chloroquine inhibited SARS-CoV-1, which also prefers the endosomal route, led to the idea that chloroquine would also work for SARS=-CoV-2 which it did not because up until Omicron all the versions have preferred direct entry using TMPRES2.